Vis enkel innførsel

dc.contributor.authorHyldbakk, Astrid
dc.contributor.authorMørch, Ýrr Asbjørg
dc.contributor.authorSnipstad, Sofie
dc.contributor.authorÅslund, Andreas
dc.contributor.authorKlinkenberg, Geir
dc.contributor.authorNakstad, Vu
dc.contributor.authorWågbø, Ane Marit
dc.contributor.authorSchmid, Ruth Baumberger
dc.contributor.authorMolesworth, Peter Patrick
dc.date.accessioned2023-04-28T13:23:15Z
dc.date.available2023-04-28T13:23:15Z
dc.date.created2022-07-22T13:22:52Z
dc.date.issued2022
dc.identifier.citationInternational Journal of Pharmaceutics: X. 2022, 4, 100124.en_US
dc.identifier.issn2590-1567
dc.identifier.urihttps://hdl.handle.net/11250/3065622
dc.description.abstractPoly (alkyl cyanoacrylate) (PACA) polymeric nanoparticles (NPs) are promising drug carriers in drug delivery. However, the selection of commercially available alkyl cyanoacrylate (ACA) monomers is limited, because most monomers were designed for use in medical and industrial glues and later repurposed for drug encapsulation. This study therefore aimed to seek out novel ACA materials for use in NP systems using a toxicity led screening approach. A multistep strategy, including cytotoxicity screening of alcohols as degradation products of PACA (44 alcohols), NPs (14 polymers), and a final in vivo study (2 polymers) gave poly (2-ethylhexyl cyanoacrylate) PEHCA as a promising novel PACA candidate. For the first time, this work presents cytotoxicity data on several novel ACAs, PEHCA in vivo toxicity data, and miniemulsion polymerisation-based encapsulation of the cabazitaxel and NR688 in novel PACA candidates. Furthermore, several of the ACA candidates were compatible with a wider selection of lipophilic active pharmaceutical ingredients (APIs) versus commercially available controls. Combined, this work demonstrates the potential benefits of expanding the array of available ACA materials in drug delivery. Novel ACAs have the potential to encapsulate a wider range of APIs in miniemulsion polymerisation processes and may also broaden PACA applicability in other fields.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleIdentification of novel cyanoacrylate monomers for use in nanoparticle drug delivery systems prepared by miniemulsion polymerisation – A multistep screening approachen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2022 The Authorsen_US
dc.source.volume4en_US
dc.source.journalInternational Journal of Pharmaceutics: Xen_US
dc.identifier.doi10.1016/j.ijpx.2022.100124
dc.identifier.cristin2039094
dc.source.articlenumber100124en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal